Clinical Trials Browser

Active not recruiting × Neoplasm Metastasis × osimertinib × Clear all

NCT03909334 2026-04-17

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05261399 2026-04-06

SAFFRON

Phase 3 Active not recruiting

Carcinoma, Neoplasm Metastasis

NCT04606771 2026-02-27

CoC

Phase 2 Active not recruiting

30 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04035486 2025-10-10

FLAURA2

Phase 3 Active not recruiting

587 enrolled 44 charts 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04676477 2025-06-22

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis